摘要
目的:探讨弥漫性大B细胞淋巴瘤(DLBCL)的临床特征和免疫分型特征。方法:分析75例DL-BCL的临床和病理资料,制作HE染色切片,并经免疫组织化学Envision plus法染色,观察CD10、bcl-6和MuM1蛋白的表达,并进一步区分生发中心B细胞(GCB细胞)和非生发中心B细胞的分化特征。结果:75例DLBCL患者,其中结内48例,结外27例,临床分期Ⅰ-Ⅱ期患者占66%(27/41),临床分期Ⅲ-Ⅳ期患者占34%(14/41);国际预后指标(IPI)0～2分者占76%(31/41),3～5分者占24%(10/41)。单个抗原的表达率,CD10(+)11例(20%),bcl-6(+)27例(49%),MuM1(+)35例(64%);18例(33%)为GCB-DLBCL,37例(67%)为非GCB-DLBCL。结论:DLBCL显示生发中心B细胞和非生发中心B细胞分化特征,中国人群DLBCL的GCB样型显著低于非GCB样型。
Objective：To study the clinical features and immunophenotypes of patients with diffuse large B-cell lymphomas. Meth- ods：Seventy-five cases of DLBCL collected during a 6-year period were studied. The clinical features and immunophenotype data were analyzed. HE stains and immunohistochemical studies using antibodies against CD10,bcl-6 和 MuM1 were performed on. The cases were then classified into germinal center B cell-like （GCB） and non-GCB subtypes. Results：Of the 75 cases of DLBCL studied, 48 cases were nodal and 27 cases were extranodal; 66 % （27/41） of the patients were classified into clinical stage Ⅰ-Ⅱ and 34% （14/ 41） were clinical stage Ⅲ-Ⅳ. IPI score, 76% （31/41）of the cases were 0-2 and 24% （10/41） were 3-5. The positive rate of CD10 ,bcl-6和 MuM1 were 20%, 49% and 64% respectively. 33% of the cases belonged to GCB and the remaining 67% were non- GCB. Conclusion：DLBCL show a diversified GCB and non-GCB differentiation. The GCB-DLBCL is significantly less common than non-GCB-DLBCL in Chinese population.
出处
《亚太传统医药》
2012年第10期51-53,共3页
Asia-Pacific Traditional Medicine
